Physical Activity and Hypoglycaemia Risk with Once-Weekly vs. Once-Daily Basal Insulin in Type 2 Diabetes
Physical Activity and Hypoglycaemia Risk with Once-Weekly vs. Once-Daily Basal Insulin in Type 2 Diabetes
Source: Post hoc analysis from ONWARDS 1–5 trials
Published in: PubMed: 40186685
2025.
1. Background
• Once-weekly basal insulin (icodec) is a breakthrough in diabetes care, recently approved by the FDA and EMA.
• It simplifies treatment with one weekly injection but raised questions about flexibility during physical activity.
2. Objective
• To compare the risk of physical activity-related hypoglycaemia between once-weekly icodec and once-daily basal insulin.
3. Methods
• Data from five phase 3 trials (ONWARDS 1–5) involving insulin-naive and insulin-experienced adults with type 2 diabetes.
• Participants self-reported hypoglycaemic events and their relation to physical activity.
4. Results
• No consistent or significant differences in hypoglycaemia risk between the two insulin types.
• Most episodes were mild to moderate.
• Recurrent events were rare and no severe episodes were reported after physical activity.
5. Conclusion
• Once-weekly insulin icodec does not increase the risk of activity-related hypoglycaemia, supporting its safety and ease of use as a modern insulin solution.https://pubmed.ncbi.nlm.nih.gov/40186685/
